Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

250
Body:Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to...
250
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

249
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
249
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

5.2K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.2K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

8.9K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
8.9K
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

6.6K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.6K
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

9.8K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimizing Clinical Study Designs for CAR-T Cell Therapy: Development of an Efficient Sampling Strategy Through Optimal Experimental Design.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Towards evolutionary guided precision medicine of acute myeloid leukemia and Fanconi anemia associated bone marrow failure.

Stem cells translational medicine·2026
Same author

Correction: Randomization in the age of platform trials: unexplored challenges and some potential solutions.

BMC medical research methodology·2026
Same author

Estimands for long-term follow-up trials in gene therapy products.

Journal of biopharmaceutical statistics·2025
Same author

Randomization in the age of platform trials: unexplored challenges and some potential solutions.

BMC medical research methodology·2025
Same author

Assessment of Wiener Process Degradation Models With Application to Amyotrophic Lateral Sclerosis Decline.

Statistics in medicine·2025

Related Experiment Video

Updated: Feb 7, 2026

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging
08:30

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging

Published on: September 11, 2011

14.9K

Implementing Optimal Designs for Dose-Response Studies Through Adaptive Randomization for a Small Population Group.

Yevgen Ryeznik1,2, Oleksandr Sverdlov3, Andrew C Hooker4

  • 1Department of Mathematics, Uppsala University, Room Å14133 Lägerhyddsvägen 1, Hus 1, 6 och 7, 751 06, Uppsala, Sweden. yevgen.ryeznik@math.uu.se.

The AAPS Journal
|July 21, 2018
PubMed
Summary
This summary is machine-generated.

Adaptive randomization procedures are crucial for dose-response studies with censored time-to-event outcomes. Multi-stage adaptive designs using randomization closely matching D-optimal allocation enhance dose-response estimation quality, especially in small trials.

Keywords:
D-optimalrandomization designsmall population grouptime-to-event outcomeunequal allocation

More Related Videos

Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression
08:42

Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression

Published on: May 19, 2015

11.2K
Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

9.2K

Related Experiment Videos

Last Updated: Feb 7, 2026

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging
08:30

X-ray Dose Reduction through Adaptive Exposure in Fluoroscopic Imaging

Published on: September 11, 2011

14.9K
Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression
08:42

Design and Implementation of an fMRI Study Examining Thought Suppression in Young Women with, and At-risk, for Depression

Published on: May 19, 2015

11.2K
Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response
06:31

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

9.2K

Area of Science:

  • Biostatistics
  • Clinical Trial Design
  • Pharmacometrics

Background:

  • Dose-response studies with censored time-to-event data require careful design to balance efficiency and bias mitigation.
  • Adaptive designs allow for dose assignment adjustments based on accumulating data, improving estimation of the dose-response curve.
  • Randomization is essential to prevent experimental biases and ensure valid statistical inference in clinical trials.

Purpose of the Study:

  • To compare various adaptive randomization procedures for implementing D-optimal designs in dose-response studies.
  • To evaluate the impact of different adaptive designs (single-stage, two-stage, multi-stage) on estimation quality.
  • To assess the robustness of these designs against experimental biases like chronological and selection biases.

Main Methods:

  • Simulation studies were conducted to compare adaptive randomization procedures for D-optimal designs.
  • Evaluated single-stage, two-stage, and multi-stage adaptive designs for dose-response studies with time-to-event outcomes.
  • Assessed the influence of randomization procedures on achieving target D-optimal allocations at each stage.

Main Results:

  • The choice of allocation design and randomization procedure significantly impacts dose-response estimation quality, particularly with small sample sizes.
  • Multi-stage adaptive designs demonstrated superior performance when implemented with randomization procedures that closely approximate the D-optimal design at each stage.
  • Small cohort sizes within multi-stage designs were found to be beneficial for maintaining design efficiency.

Conclusions:

  • For dose-response studies with censored time-to-event outcomes and small to moderate sample sizes, multi-stage adaptive designs are recommended.
  • Selecting a randomization procedure that accurately achieves the D-optimal allocation at each interim analysis is critical for optimal performance.
  • These findings provide guidance for clinical investigators in choosing appropriate randomization strategies for robust dose-response studies.